OR WAIT null SECS
Nonprofit will continue industry collaborations on shared resources for drug discovery and development
Just over a year old now, TransCelerate BioPharma Inc. (Philadelphia) is expanding both its projects and its membership. The newest member of the nonprofit industry collaboration is Cubist Pharmaceuticals, which brings the total membership to 18, including the ten original founding companies.
TransCelerate is set up to coordinate “pre-competitive” activities that benefit drug discovery and development; most recently it set up a Clinical Trial Comparator Network to enable companies to obtain comparator drugs for clinical trials more efficiently. That, along with a (Clinical) Site Qualification and Training project, is now being expanded. Ongoing programs for risk-based monitoring of studies, clinical data standards and a Shared Investigator Portal are advancing.
To this list of programs, three new initiatives have begun:
The founding membership of TransCelerate is AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, J&J, Pfizer, Roche and Sanofi. Additional members now include Astellas Pharma, Biogen Idec, Braeburn Pharmaceuticals, Cubist, EMD Serono, Forest Research Institute (part of Forest Laboratories), Onyx Pharmaceuticals and UCB. TransCelerate continues to solicit new members.